Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib-based versus trastuzumab + pertuzumab taxane neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
ChiCTR2400079934Phase 4Recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pyrotinib, trastuzumab and pertuzumab in breast cancer (3 arms), sponsored by Foshan First People's Hospital. Primary endpoint: Pathological complete response rate. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400079934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079934.